Answers are grounded in this paper and cite their sources.
Background Eosinophilic inflammation has long been associated with asthma. Looking at systemic and airway eosinophilia , we have recently identified a group of patients exhibiting diffuse eosinophilic inflammation. Among the mechanisms governing eosinophilic inflammation, IgE-mediated mast cell activation is a key event leading to eosinophilia in atopic asthmatics. Methods We conducted a retrospective study on our asthma clinic database containing more than 1500 patients and identified 205 asthmatics with successful sputum induction and concordant eosinophilic phenotype. This phenotype was defined as a sputum eosinophil count ≥ 3% and a blood eosinophils concentration ≥ 400 cells/mm 3 . IgE-high atopic phenotype was characterized by the presence of at least one positive specific IgE (> 0.35 kU/L) to common aeroallergens and a raised total serum IgE (≥ 113 kU/L). Results The largest group of asthmatics displaying concordant eosinophilic phenotype had a raised total serum IgE and atopy (45%). IgE-low non-atopic concordant eosinophilic asthma was a predominantly late onset disease, exhibited a more intense airway eosinophilic inflammation ( P < 0.05), required more often maintenance treatment with oral corticosteroids ( P < 0.05) but, surprisingly, had a reduced level of bronchial hyperresponsiveness to methacholine ( P < 0.05) despite similar baseline airway calibre impairment. Conclusion The more severe airway eosinophilic inflammation in IgE-low non-atopic asthmatics despite similar treatment with ICS and a higher burden of OCS points to a certain corticosteroid resistance in this asthma phenotype.
No takes yet. Share an insight, caveat, or question.
Gerday et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: